Hear how the experts successfully navigate common barriers to prior authorizations for PCSK9 inhibitors. Learn how to leverage the EHR and online resources to support prior authorization approvals and effective appeals. The faculty will also share best practices for streamlining the process for both colleagues and patients.

Target Audience
The intended audience is cardiovascular team clinicians who participate in Transform LDL-C Risk and who coordinate treatment plans and/or deliver care for patients with hypercholesterolemia.

Chair 
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina

Faculty
Kim K. Birtcher, PharmD, MS, AACC, FNLA
Clinical Professor
University of Houston College of Pharmacy

Carl E. Orringer, MD, FACC
Associate Professor of Medicine
Director, Preventive Cardiovascular Medicine
Cardiovascular Division
University of Miami Miller School of Medicine

Acknowledgments
Educational grant support provided by REGENERON

Disclaimer: This activity does not offer credit.